Primary antibody deficiencies (PADs) are a heterogeneous spectrum of conditions characterized by the marked reduction in blood levels of at least one main immunoglobulin (Ig) class. PADs account for about half of the cases of primary immunodeficiency. Ig replacement therapy has dramatically changed the management of PADs. Nevertheless, children with PADs are exposed to complications, in particular pulmonary complications, even if in Ig replacement therapy. These complications could have long-term consequences in children with PADs. In recent years, new strategies and technologies have changed the management of children with PADs, from diagnosis to treatment and follow-up.
The topic objective is to highlight recent advances in PADs management and address the challenges that still need improvement. We aim to improve an early diagnosis of PADs, effective, cost and time-sparing treatment with low side effects, and new strategies to detect complications during the follow-up.
Submissions may address, but are not limited to:
1) Novel therapy options
2) Current treatment strategies
3) New technologies for diagnosis and follow-up of PADs
3) Biomarker discovery
4) Observational descriptive studies of PADs
5) Case reports and case series that highlight current challenges in PADs management
6) Epidemiology of inequalities of PADs management within the same country and across different countries
Keywords:
Primary Antibody Deficiencies, Human inborn errors of immunity, Multiple breath washout, Immunoglobulin replacement therapy, Biomarkers, Magnetic Resonance Imaging
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Primary antibody deficiencies (PADs) are a heterogeneous spectrum of conditions characterized by the marked reduction in blood levels of at least one main immunoglobulin (Ig) class. PADs account for about half of the cases of primary immunodeficiency. Ig replacement therapy has dramatically changed the management of PADs. Nevertheless, children with PADs are exposed to complications, in particular pulmonary complications, even if in Ig replacement therapy. These complications could have long-term consequences in children with PADs. In recent years, new strategies and technologies have changed the management of children with PADs, from diagnosis to treatment and follow-up.
The topic objective is to highlight recent advances in PADs management and address the challenges that still need improvement. We aim to improve an early diagnosis of PADs, effective, cost and time-sparing treatment with low side effects, and new strategies to detect complications during the follow-up.
Submissions may address, but are not limited to:
1) Novel therapy options
2) Current treatment strategies
3) New technologies for diagnosis and follow-up of PADs
3) Biomarker discovery
4) Observational descriptive studies of PADs
5) Case reports and case series that highlight current challenges in PADs management
6) Epidemiology of inequalities of PADs management within the same country and across different countries
Keywords:
Primary Antibody Deficiencies, Human inborn errors of immunity, Multiple breath washout, Immunoglobulin replacement therapy, Biomarkers, Magnetic Resonance Imaging
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.